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1. Introduction 
Vertebrate blood contains an insulin-like activity 
distinguishable from insulin by the lack of cross- 
reactivity with antibodies to insulin [1,2]. The low 
molecular weight form of this non-suppressible 
insulin-like activity (NSILA-s) [2] could be identified 
with 2 polypeptides isolated from human plasma [3]. 
Besides having insulin-like activity, both polypeptides 
display growth-promoting activity on chick embryo 
fibroblasts if added to a chemically defined medium 
at a concentration f 10 -9 M [3]. The structural 
similarity of these 2 substances with the amino acid 
sequence of insulin has prompted us to name these 
polypeptides insulin-like growth factors (IGF I and II) 
[4]. The total primary structure of IGF I has been 
reported [5]. We now have determined the complete 
amino acid sequence of IGF II. 
2. Methods 
IGF II was isolated from a human plasma fraction 
as in [3]. Modification byS- [14C] carboxymethylation 
or S-aminoethylation, cleavage by trypsin, chymo- 
trypsin and 0.25 M acetic acid and separation of the 
resulting peptides followed the methods used for the 
sequence determination f IGF I [5]. Peptides A-1 
and A-7 (see fig.l) had to be separated from each 
other on SP-Sephadex C-25 in 30% aqueous acetic 
acid by elution with a NaC1 gradient. The 28 residue 
peptide A-5 (see fig.l)was further digested with 
thermolysin and the peptides eparated by paper 
electrophoresis, at pH 6.5. Sequence determination 
was carried out on an automatic sequencer (Beckman 
Model 890 B, updated) as in [5]. Repetitive yields 
were from 90-95%. 
3. Results 
The complete amino acid sequence of IGF II is 
shown in fig. 1, together with notations indicating the 
peptides and the methods used in establishing the 
structure. The sequence of residues 1-31 has been 
determined by Edman degradation of S-pyridyl- 
ethylated IGF II [4]. The proposed sequence was 
confirmed by sequence analysis of fragments obtained 
with trypsin, chymotrypsin and acetic acid. The lack 
of N-terminal Ala in about 25% of all molecules of 
IGF II could be confirmed by Edman degradation of
peptides T-1 and A-1. Residues 32-49 were deter- 
mined on peptides T-3, T-4, T-6 and T-7 and on 
thermolytic subpeptides of A-5, residues 50-67 on 
peptides T-8, C-6 and C-8. Further confirmation of 
the sequence was obtained from supplementary 
analyses of overlapping peptides as indicated in fig.1. 
The amino acid composition derived from the sequence 
is shown in table 1, the calculated minimal mol. wt 
is 7471. Earlier determinations had shown that the 
6 half-cystine residues form 3 intrachain disulfide 
bridges [3]. 
4. Discussion 
The primary structure of IGF II is similar to that 
of IGF I. If aligned as in fig.2, 45 of 73 amino acid 
positions, or 62%, are identical. Their most character- 
istic common feature is the homology to proinsulin. 
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Fig. 1. Amino acid sequence of human IGF-II and a schematic outline of the data supporting the sequence. The letter code 
indicates the cleavage method used to produce the peptides: T, trypsin; C, chymotrypsin; A, acetic acid; T1, thermolysin. Sequence 
data obtained by automatic Edman degradation of the intact protein (31 residues, [4]) are not included in fig.1. To indicate the 
method of sequential degradation and of identification of residues, the following symbols are used: (~) automatic Edman degrada- 
tion and amino acid analysis of the hydrolyzed PTH-derivatives; (~-) automatic Edman degradation and gas chromatography of 
PTH-derivatives; (=) automatic Edman degradation and thin-layer chromatography of the PTH-derivatives; (--~-) automatic Edman 
degradation and high-pressure liquid chromatography of PTH-derivatives; (A_) automatic Edman degradation and liquid scintilla- 
tion counting; (7) digestion with aminopeptidase M or aminopeptidase from Aeromonas and amino acid analysis; (7-) dansylation 
and thin layer chromatography; (~-) digestion with carboxypeptidase C and amino acid analysis; (,_x) manual Edman degradation 
(direct and/or subtractive). Peptides marked with an asterisk were further digested with trypsin or staphylococcal protease, the 
fragments eparated and analyzed for their amino acid composition. 
As proinsulin, IGF consists of the domains B, C and 
A. The sequence similarity of IGF to proinsulin is 
confined to the B and A domain (fig.2). The C 
domain (connecting peptide) of IGF II is only 8 
residues long compared to 12 in IGF I and to 35 in 
proinsulin. It has been pointed out tb.t a connecting 
peptide as short as 3 residues suffices to span residues 
B30 and A1 and to allow the proper 3-dimensional 
folding of insulin (cf. [6] ). 
Out of 19 invariant residues present in all insulins 
so far sequenced, the same 17 residues are present in 
IGF II as in IGF I. In fact, a 3-dimensional model of 
IGF I could be constructed very similar to the one of 
insulin [6],  a further corollary to the postulated 
evolutionary relationship of IGF and insulin. 
Another feature common to IGF I and II, but not 
found in proinsulin, is a C-terminal extension 
(D domain) which is 6 residues long in IGF II, 2 
residues shorter than in IGF I. An analogous exten- 
sion in the nucleotide sequence of proinsulin messenger 
RNA has been described in [7]. Although this 
nucleotide sequence shows no homology to the 
D domain of IGF, the former might be an evolutionary 
relic of a common ancestor of  proinsulin and IGF. 
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Table 1 
Amino acid composition of IGF I and II (no./molecule 
from amino acid sequence) 
Number of Identities 
Residue IGF-I IGF-II 
Lys 3 1 
Arg 6 8 
Asp 4 3 
Asn 1 0 
Thr 3 4 
Ser 5 7 
Glu 4 6 
Gin 2 1 
Pro 5 3 
Gly 7 5 
Ala 6 5 
Cys 6 6 
Val 3 4 
Met 1 0 
lie 1 1 
Leu 6 6 
Tyr 3 3 
Phe 4 4 
Total residues 70 67 
Calc. mol. wt 7649 7471 
HI RSI IGF - I  IGF-I I  
HI 
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IGF - I 
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39 25 24  
76 ~24 26 
47 51 76 
Percent Identity 
Fig. 3. Matrix comparing sequence identities between human 
insulin (HI), rattlesnake insulin (RSI) and A and B domains 
of IGF I and II. The data for insulins are taken from [10]. 
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Fig.2. Primary structure of human proinsulin (HPI), IGF I and IGF II. Alignment has been so chosen as to give maximal homology. 
Boxes in solid lines indicate residues identical in IGF I and II; boxes in broken lines indicate residues identical in HPI and in 
IGF I and/or II. 
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A somewhat different extension beyond residue 
A21 has been found in nerve growth factor, which 
may be another, though disputed, rhember of the 
insulin family [8]. The extension in nerve growth 
factor has been interpreted as the result of  a gene 
duplication [8]. In relaxin, the 4th member of this 
family, neither a C nor a D domain has been found as 
yet [9]. 
Based on the differences in amino acid sequence 
between insulins from different classes of vertebrates 
and IGF I, we have suggested that the divergence of 
IGF and proinsulin from a common ancestor took 
place before the appearance of the vertebrates [5]. 
Figure 3 lists the % and no. of identities in amino acid 
positions of human and rattlesnake insulin and of the 
corresponding A and B domains of IGF I and II. The 
% identity between human and rattlesnake insulin is 
76 [10], the same as between IGF I and II (A and B 
domains). Under the assumption that the A and B 
domains of IGF had the same rate of evolution as A 
and B chains of insulin, the time of divergence of 
IGF I and II can thus be placed at about the time of 
the appearance of the first mammals. 
As to the biological function of IGF, evidence is 
accumulating that IGF is a growth hormone-dependent 
hormone [11,12], thus belonging to a class of  growth 
factors called somatomedins (cf. [13]). It remains to 
be seen whether other somatomedins such as somato- 
medin A, somatomedin C and multiplication stimulat- 
ing activity (MSA) (cf. [13] ) are as close homologues 
of proinsulin as is IGF. 
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